Document is current
Any future updates will be listed below
-
Authors
McKenna, Lindsay
Frick, Mike https://orcid.org/0000-0002-3316-1930
Angami, Ketholelie
Dubula, Vuyiseka
Furin, Jennifer
Harrington, Mark
Hausler, Harry
Heitkamp, Petra
Herrera, Rosa
Lynch, Sharonann
Mitnick, Carole D. https://orcid.org/0000-0002-3455-658X
Moses, Gloriah Kerubo
Ndjeka, Norbert
Nyang’wa, Bern-Thomas
Palazuelos, Lindsay
Ulysse, Patrick
Pai, Madhukar https://orcid.org/0000-0003-3667-4536
- License Information
-
More Information
Article History
First Online: 10 January 2023
Competing interests
: J.F. received grant funding from the Stop TB Partnership’s Global Drug Facility to support the rollout of child-friendly formulations of second-line drugs. M.P. has no financial or industry conflicts to disclose; he serves as an advisor to the WHO, Foundation for Innovative New Diagnostics, Stop TB Partnership and Bill & Melinda Gates Foundation. B.-T.N. is employed by Médecins Sans Frontières, the sponsor of the TB-PRACTECAL trial that developed a 6-month multidrug-resistant/rifampicin-resistant TB (RR-/MDR-TB) regimen. Through grants to her institution, C.D.M. receives research funding to study all-oral shortened regimens for treatment of drug-resistant TB containing bedaquiline, delamanid, linezolid, clofazimine, levofloxacin, moxifloxacin and pyrazinamide.
